Lilly may boost biotech business through follow-on biologics

12/11/2008 | Reuters · Wall Street Journal, The

Eli Lilly and Co. CEO John Lechleiter said the company is "very much considering" developing follow-on biologics but clarified that the firm has yet to include such products in its pipeline. The drugmaker "could do particularly well" in such a venture because of its protein-engineering capabilities, said Steven Paul, president of Lilly Research Laboratories.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC